Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Equity to Asset 0.38
BIOS's Equity to Asset is ranked higher than
60% of the 482 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.46 vs. BIOS: 0.38 )
BIOS' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.66
Current: 0.38

0.27
0.66
F-Score: 2
Z-Score: 1.05
M-Score: -1.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -0.83
BIOS's Operating margin (%) is ranked lower than
53% of the 486 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.80 vs. BIOS: -0.83 )
BIOS' s 10-Year Operating margin (%) Range
Min: -11.69   Max: 4.61
Current: -0.83

-11.69
4.61
Net-margin (%) -8.27
BIOS's Net-margin (%) is ranked lower than
55% of the 486 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.37 vs. BIOS: -8.27 )
BIOS' s 10-Year Net-margin (%) Range
Min: -16.05   Max: 9.77
Current: -8.27

-16.05
9.77
ROE (%) -19.64
BIOS's ROE (%) is ranked lower than
55% of the 477 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.99 vs. BIOS: -19.64 )
BIOS' s 10-Year ROE (%) Range
Min: -105.65   Max: 34.72
Current: -19.64

-105.65
34.72
ROA (%) -7.43
BIOS's ROA (%) is ranked lower than
54% of the 485 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.42 vs. BIOS: -7.43 )
BIOS' s 10-Year ROA (%) Range
Min: -51.46   Max: 18.84
Current: -7.43

-51.46
18.84
ROC (Joel Greenblatt) (%) -4.26
BIOS's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 485 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.02 vs. BIOS: -4.26 )
BIOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -451.43   Max: 201.57
Current: -4.26

-451.43
201.57
Revenue Growth (%) 15.10
BIOS's Revenue Growth (%) is ranked higher than
92% of the 330 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.90 vs. BIOS: 15.10 )
BIOS' s 10-Year Revenue Growth (%) Range
Min: -35   Max: 15.9
Current: 15.1

-35
15.9
EPS Growth (%) -14.80
BIOS's EPS Growth (%) is ranked higher than
63% of the 297 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.60 vs. BIOS: -14.80 )
BIOS' s 10-Year EPS Growth (%) Range
Min: -82.7   Max: 40.2
Current: -14.8

-82.7
40.2
» BIOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

BIOS Guru Trades in Q1 2013

Jim Simons 510,586 sh (+46.06%)
Mario Gabelli 23,200 sh (+17.77%)
Jeff Auxier 33,960 sh (-46.61%)
» More
Q2 2013

BIOS Guru Trades in Q2 2013

Alan Fournier 1,638,263 sh (New)
Chuck Royce 4,000 sh (New)
Paul Tudor Jones 11,200 sh (New)
Mario Gabelli 23,000 sh (-0.86%)
Jeff Auxier 12,578 sh (-62.96%)
Jim Simons 150,150 sh (-70.59%)
» More
Q3 2013

BIOS Guru Trades in Q3 2013

Steven Cohen 17,373 sh (New)
Louis Moore Bacon 100,000 sh (New)
Paul Tudor Jones 31,300 sh (+179.46%)
Alan Fournier 3,543,900 sh (+116.32%)
Mario Gabelli 24,700 sh (+7.39%)
Jim Simons Sold Out
Chuck Royce Sold Out
Jeff Auxier Sold Out
» More
Q4 2013

BIOS Guru Trades in Q4 2013

Kyle Bass 400,000 sh (New)
Ron Baron 37,530 sh (New)
Pioneer Investments 280,320 sh (New)
Mario Gabelli 57,400 sh (+132.39%)
Alan Fournier 5,096,473 sh (+43.81%)
Louis Moore Bacon Sold Out
Paul Tudor Jones 12,500 sh (-60.06%)
Steven Cohen 5,700 sh (-67.19%)
» More
» Details

Insider Trades

Latest Guru Trades with BIOS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2013-12-31 New Buy$5.65 - $8.58 $ 7.476%37530
Mario Gabelli 2013-12-31 Add 132.39%$5.65 - $8.58 $ 7.476%57400
Wilbur Ross 2012-12-31 Sold Out 0.03%$8.85 - $10.92 $ 7.47-24%0
Mario Gabelli 2012-12-31 Add 40.71%$8.85 - $10.92 $ 7.47-24%19700
Wilbur Ross 2012-09-30 Reduce -86.94%0.18%$6.32 - $9.11 $ 7.47-2%39456
Mario Gabelli 2012-09-30 New Buy$6.32 - $9.11 $ 7.47-2%14000
Joel Greenblatt 2012-06-30 Sold Out 0.12%$6.52 - $7.85 $ 7.475%0
Joel Greenblatt 2012-03-31 Add 187.1%0.08%$5.22 - $6.97 $ 7.4730%200607
Wilbur Ross 2012-03-31 Reduce -25.51%0.04%$5.22 - $6.97 $ 7.4730%331156
Joel Greenblatt 2011-12-31 New Buy0.05%$5.14 - $6.99 $ 7.4725%69873
Wilbur Ross 2011-06-30 Reduce -25.85%0.07%$4.205 - $7.84 $ 7.4720%602341
Wilbur Ross 2011-03-31 Add 455.85%0.21%$4.12 - $5.5 $ 7.4759%812354
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on BioScrip, Inc.

Baron Funds Comments on BioScrip Inc. - Feb 26, 2014

BioScrip, Inc. (BIOS), an operator of infusion therapy pharmacies, fell 16.5% for the Fund in the quarter. While the company continues to execute its strategy of consolidating the infusion services industry, it stumbled after a non-core legacy business performed worse than expected. While the miscue is not dire for the company, it hurt management's credibility after it had to reset guidance. We continue to believe there is substantial value and growth in the core infusion business, and that this has been validated by CVS's purchase in December of the number two player in the space, Coram, for a very high multiple of cash flow.



From Ron Baron (Trades, Portfolio)'s Baron Funds fourth quarter 2013 letter to shareholders.

Check out Ron Baron latest stock trades

Top Ranked Articles about BioScrip, Inc.

Baron Funds Comments on BioScrip Inc.
BioScrip, Inc. (BIOS), an operator of infusion therapy pharmacies, fell 16.5% for the Fund in the quarter. While the company continues to execute its strategy of consolidating the infusion services industry, it stumbled after a non-core legacy business performed worse than expected. While the miscue is not dire for the company, it hurt management's credibility after it had to reset guidance. We continue to believe there is substantial value and growth in the core infusion business, and that this has been validated by CVS's purchase in December of the number two player in the space, Coram, for a very high multiple of cash flow. Read more...
BIOS, INWK, LAYN - Mario Gabelli Update
The investing phenomenon Mario Gabelli, founder, chairman and CEO of GAMCO Investors, holds a number of stocks at or near a 52-week low, including Layne Christensen Company (LAYN), InnerWorkings Inc. (INWK) and BioScrip Inc. (BIOS), all down between 23% and 60% over 12 months. Check out these three holdings for recent trading action and possible deep value, along with the latest company financials as of the third quarter. Read more...

Ratios

vs
industry
vs
history
P/B 1.40
BIOS's P/B is ranked higher than
72% of the 471 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.70 vs. BIOS: 1.40 )
BIOS' s 10-Year P/B Range
Min: 0.3   Max: 3.1
Current: 1.4

0.3
3.1
P/S 0.57
BIOS's P/S is ranked higher than
54% of the 490 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.46 vs. BIOS: 0.57 )
BIOS' s 10-Year P/S Range
Min: 0.04   Max: 1.89
Current: 0.57

0.04
1.89
EV-to-EBIT 1000.00
BIOS's EV-to-EBIT is ranked lower than
75% of the 457 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.48 vs. BIOS: 1000.00 )
BIOS' s 10-Year EV-to-EBIT Range
Min: 5.7   Max: 1645.4
Current: 1000

5.7
1645.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.60
BIOS's Price/DCF (Projected) is ranked lower than
58% of the 240 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.30 vs. BIOS: 2.60 )
BIOS' s 10-Year Price/DCF (Projected) Range
Min: 0.72   Max: 12.03
Current: 2.6

0.72
12.03
Price/Median PS Value 2.40
BIOS's Price/Median PS Value is ranked lower than
75% of the 460 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. BIOS: 2.40 )
BIOS' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 3.81
Current: 2.4

0.22
3.81
Earnings Yield (Greenblatt) 0.10
BIOS's Earnings Yield (Greenblatt) is ranked lower than
65% of the 467 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.40 vs. BIOS: 0.10 )
BIOS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 17.5
Current: 0.1

0.1
17.5
Forward Rate of Return (Yacktman) 0.35
BIOS's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 279 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.93 vs. BIOS: 0.35 )
BIOS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.9   Max: 9.1
Current: 0.35

-5.9
9.1

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:MM6.Germany
BioScrip, Inc., was incorporated in Delaware in 1996 as MIM Corporation. The Company is a provider of pharmacy and home health services that partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of cost-effective access to prescription medications and home health services. Its platform provides nationwide service capabilities and the ability to deliver clinical management services that offer patients a high-touch, community-based and home-based care environment. Its core services are provided in coordination with, and under the direction of the patient's physician. Its home health professionals, including pharmacists, nurses, respiratory therapists and physical therapists, work with the physician to develop a plan of care suited to its patients' specific needs. Whether in the home, physician office, ambulatory infusion center or other alternate site of care, it provides products, services and condition-specific clinical management programs, often tailored to improve the care of individuals with complex health conditions such as gastrointestinal abnormalities, HIV/AIDS, cancer, iron overload, multiple sclerosis, organ transplants, bleeding disorders, rheumatoid arthritis, immune deficiencies and congestive heart failure. Its Infusion/Home Health Services segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment products and services. Infusion services include the dispensing and administering of infusion-based drugs, which typically require additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes. Home infusion services also include the dispensing of self-injectible therapies. Home health services include the provision of skilled nursing services and therapy visits, private duty nursing services, hospice services, rehabilitation services and medical social services to patients primarily in their home. Its Pharmacy Services segment consists of its traditional and specialty pharmacy mail operations, community pharmacies and integrated pharmacy benefit management ("PBM") services, which includes discount cash card programs. These segment operations are designed to offer customers and patient's cost-effective delivery of traditional and specialty pharmacy products and services. The services also include care management programs customized to each patient's care plan in coordination with the patient's physician. The Company's main competitors include Option Care, Inc. (a subsidiary of Walgreen Co.), Apria Healthcare Group Inc. (which includes its subsidiary, Coram, Inc.), Critical Care Systems, Inc. and Accredo Health Group, Inc. (both subsidiaries of Medco Health Solutions, Inc.), Omnicare, Inc., various regional providers and local providers of alternate site healthcar

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide